Core Viewpoint - Hunan Fangsheng Pharmaceutical Co., Ltd. has signed a contract with Liao Ning Yifan Pharmaceutical Co., Ltd. to acquire the marketing authorization for "Compound Dexamethasone Cream," which includes ownership of the drug formula, production process, technical secrets, and related patents and data [2][11]. Group 1: Transaction Overview - The company has entered into a technology transfer contract to acquire the marketing authorization for "Compound Dexamethasone Cream" [2]. - The transaction does not constitute a related party transaction or a major asset restructuring, and it is within the approval authority of the chairman, thus not requiring board or shareholder approval [2]. - The transfer fee is structured in three phases, with 30% payable within five working days of signing, another 30% upon completion of production site change, and 40% after receiving the approval notice from the drug review center [8]. Group 2: Market Situation - There are 103 companies in China that have obtained production licenses for "Compound Dexamethasone Cream" [3]. - The sales figures for the cream in physical pharmacies were 175 million yuan in the first half of 2025 and projected to reach 429 million yuan in 2024 [3]. - The global market sales for dexamethasone formulations were approximately $1.198 billion in 2022 and $1.203 billion in 2023 [3]. Group 3: Impact on the Company - The acquisition aligns with the company's strategy to become a health industry group focused on innovative traditional Chinese medicine, enhancing its product pipeline and potentially providing new profit growth points [11]. - The addition of this dermatological product category is expected to strengthen the company's market competitiveness and facilitate industry chain integration and expansion [11].

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) has signed a technology transfer contract with Yifan Pharmaceutical to acquire the marketing authorization for "Compound Dexamethasone Acetate Cream," which includes ownership of the drug prescription, production process, technical secrets, related patents, and technical data [1] Group 1: Strategic Development - The company aims to become a health industry group centered on innovative traditional Chinese medicine, continuously increasing R&D investment while also acquiring products with development potential to enrich its product pipeline [1] - The acquisition of the marketing authorization is aligned with the company's development strategy, facilitating industry chain integration and expansion, thereby enhancing market competitiveness [1] Group 2: Product Expansion - Following the acquisition, the company's dermatological product category will be effectively expanded, with the potential for new profit growth through brand empowerment within the group [1]

公司确定"打造成为一家以中药创新药为核心的健康产业集团"的发展战略以来，持续加大研发投入，并 同步通过外购来储备具有发展潜力的产品，以丰富公司产品管线，从而加快发展步伐。本次受让完成 后，公司皮肤病药物品类得到有效扩充，后续通过集团的品牌赋能，有望为公司提供新的利润增长点。 本次受让药品上市许可符合公司发展战略，有利于推动产业链整合和扩张，提升公司的市场竞争力。 智通财经APP讯，方盛制药(603998.SH)发布公告，2025年9月30日，公司与亿帆药业签订了《技术转让 (技术秘密)合同》，决定受让其"复方醋酸地塞米松乳膏"药品上市许可(包括但不限于药品处方、生产工 艺、技术秘密、与标的品种相关的专利、技术资料等数据的所有权)。 ...